Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/3033% below fair value
$0.91−0.07 (-7.38%)
Close on Nov 20, 2026Market cap $241.49MP/E –Yield –
Autolus Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Autolus Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$232.73M. For fiscal 2025 it was -$302.61M. The highest annual figure on record is -$11.70M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$302.61M | – |
| FY2024 | Dec 31, 2024 | -$228.35M | – |
| FY2023 | Dec 31, 2023 | -$156.57M | – |
| FY2022 | Dec 31, 2022 | -$123.15M | – |
| FY2021 | Dec 31, 2021 | -$126.72M | – |
| FY2020 | Dec 31, 2020 | -$132.44M | – |
| FY2018 | Sep 30, 2018 | -$40.66M | – |
| FY2017 | Sep 30, 2017 | -$19.24M | – |
| FY2016 | Sep 30, 2016 | -$11.70M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$25.98M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$68.01M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$66.44M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$72.31M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$80.06M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$83.81M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$49.05M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$86.33M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$51.92M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$41.05M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$26.31M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$41.69M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$42.54M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$46.04M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$15.20M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$39.24M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$33.20M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$43.11M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$29.46M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$26.67M | – |
See a number that looks wrong?